ClinicalTrials.gg
RecruitingNCT06554795Updated Jun 5, 2026

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2 interventional study of DB-1419 in Solid Tumor, Adult, sponsored by DualityBio Inc.. Recruiting at 36 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by DualityBio Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
360
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

Read the detailed description

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1419 in Participants with Advanced/Metastatic Solid Tumors

02

Conditions studied

  • Solid Tumor, Adult
03

In context

Lead sponsor

DualityBio Inc. is the lead sponsor of 12 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged ≥ 18 years at the time of voluntarily signing .
  2. or cytologically confirmed unresectable advanced/ solid tumor that has or progressed on or after standard systemic treatments, or refused the standard treatment, or for which no standard treatment is available.
  3. At least one as assessed by the Investigator according to v1.1 criteria (Only applicable to backfill participants in phase 1a and participants in phase 1b/2a). CRPC participants with bone-only disease may be eligible on a case-by-case basis after discussion with the Medical Monitor.
  4. Has a of ≥ 3 months.
  5. Has an (ECOG) performance status (PS) of 0-1.
  6. Has ≥ 50% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before enrollment.
  7. Has adequate organ function within 7 days prior to the first dose of study treatment.
  8. Has adequate treatment prior to the first dose of study treatment.
  9. Is willing to provide pre-existing resected tumor samples when available or undergo fresh tumor if feasible for the measurement of B7-H3 level and other biomarkers if no .

    Note: there is no minimum B7-H3 expression level mandatory for entry into the study.

  10. Is capable of comprehending study procedures and risks outlined in the informed consent and able to provide written consent and agree to comply with the requirements of the study and the schedule of assessments.
  11. Male and female participants of reproductive/ must agree to avoid pregnancy during the study and for at least 4 months and 7 months after the last dose of study treatment, respectively.
  12. Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 4 months after the final study treatment administration. Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and for at least 7 months after the final study treatment administration.

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment with B7-H3 targeted therapy or prior treatment with ADC containing a topoisomerase I inhibitor payload.
  2. Has a medical history of symptomatic congestive heart failure ( [NYHA] classes II-IV or serious cardiac arrhythmia requiring treatment.
  3. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
  4. Has an average of Fredericia's formula- corrected interval (QTcF) prolongation to > 470 millisecond (ms) in males and females based on a 12-lead (ECG) in triplicate.
  5. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis which needs and antibiotics) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
  6. Has a history of underlying pulmonary disorder including, but not limited to, pulmonary emboli within 3 months of the start of study treatment, severe asthma, severe , restrictive lung disease, and other pulmonary compromise or requirement for supplemental oxygen.
  7. Has an active disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids, or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is allowed.
  8. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals within 2 weeks before first dose of study treatment.
  9. Know (HIV) infection.
  10. Has active viral hepatitis.
  11. Is a lactating mother, or pregnant as confirmed by pregnancy tests performed within 7 days prior to enrollment.
  12. Has spinal cord compression or clinically active central nervous system (CNS) , defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with asymptomatic who are radiologically and neurologically stable for at least 4 weeks following CNS-directed therapy, and are on stable or decreasing doses of corticosteroids equivalent to ≤10 mg/day prednisone are eligible for study entry.
  13. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to v 5.0, Grade ≤ 1 or baseline.
  14. Has a prior history of immune-related adverse event that required permanent discontinuation per NCCN guidelines.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Dose Level 1

    Enrolled subjects will receive DB-1419 at Dose Level 1

    Drug: DB-1419

  • Experimental
    Dose Level 2

    Enrolled subjects will receive DB-1419 at Dose Level 2

    Drug: DB-1419

  • Experimental
    Dose Level 3

    Enrolled subjects will receive DB-1419 at Dose Level 3

    Drug: DB-1419

  • Experimental
    Dose Level 4

    Enrolled subjects will receive DB-1419 at Dose Level 4

    Drug: DB-1419

  • Experimental
    Dose Level 5

    Enrolled subjects will receive DB-1419 at Dose Level 5

    Drug: DB-1419

  • Experimental
    Dose Level 6

    Enrolled subjects will receive DB-1419 at Dose Level 6

    Drug: DB-1419

  • Experimental
    Dose Expansion 1

    Drug: DB-1419

  • Experimental
    Dose Expansion 2

    Drug: DB-1419

  • Experimental
    Dose Expansion 3

    Drug: DB-1419

  • Experimental
    Dose Expansion 4

    Drug: DB-1419

  • Experimental
    Dose Expansion 5

    Drug: DB-1419

  • Experimental
    Dose Expansion 6

    Drug: DB-1419

  • Experimental
    Dose Expansion 7

    Drug: DB-1419

  • Experimental
    Dose Expansion 8

    Drug: DB-1419

  • Experimental
    Dose Level 7

    Enrolled subjects will receive DB-1419 at Dose Level 7

    Drug: DB-1419

  • Experimental
    Dose Level 8

    Enrolled subjects will receive DB-1419 at Dose Level 8

    Drug: DB-1419

  • Experimental
    Dose Level 9

    Enrolled subjects will receive DB-1419 at Dose Level 9

    Drug: DB-1419

Interventions

  • DrugDB-1419

    Administered Injection of Vein (I.V.)

06

What researchers measure

Primary outcomes

  1. Phase 1/2a: Percentage of Participants with Adverse events (AE) serious AE (SAE)

    Percentage of participants with TEAEs graded according to NCI CTCAE v5.0

    Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first

  2. Phase 1/2a: Percentage of Participants with serious AE (SAE)

    Percentage of participants with SAEs graded according to NCI CTCAE v5.0

    Time frame: Up to 90 days after last study treatment administration or before starting new anticancer treatment, whichever comes first

  3. Phase 1a: Maximum Tolerated Dose (MTD)

    MTD on the data collected during Part 1

    Time frame: From first study treatment administration until the initiation of Phase1b/2a, approximately up to 12 months.

  4. Phase 1a: Recommended Phase 2 Dose (RP2D)

    RP2D of DB-1419 based on the data collected during Part 1

    Time frame: From first study treatment administration until the initiation of Phase 1b/2a, approximately up to 12 months.

  5. Phase 1b/2a: Objective Response Rate (ORR) determined by Investigator per RECIST v1.1

    The percentage of subjects with best overall response of CR and PR

    Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.

Secondary outcomes

  1. Phase 1a: ORR determined from tumor assessments by Investigator per RECIST v1.1

    The percentage of subjects with best overall response of CR and PR

    Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months.

  2. Phase 1/2a: Progression free survival (PFS) determined from tumor assessments by Investigator per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1

    PFS will be determined from tumor assessments by investigator per RECIST 1.1

    Time frame: Up to disease progression or death or before starting new anticancer treatment or withdrawal from the trial, whichever comes first, approximately up to 12 months

  3. Phase 1/2a: OS

    overall survival (OS)

    Time frame: From the start date of study drug to the date of death due to any cause, whichever occurs first, approximately up to 12 months after last patient first dose.

  4. Phase 1/2a: AUC0-last

    the area under the concentration-time curve from time zero to the last quantifiable concentration

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  5. Phase 1/2a: AUC0-tau

    the area under the concentration-time curve from time zero to time tau

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  6. Phase 1/2a: AUCinf

    the area under the concentration-time curve from time zero to infinite

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  7. Phase 1/2a: Cmax

    peak observed concentration

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  8. Phase 1/2a: Tmax

    Time to Cmax

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  9. Phase 1/2a: Ctrough

    trough concentration

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  10. Phase 1/2a: ADA prevalence

    the proportion of participants who are ADA positive at any point in time (at baseline and post-baseline)

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

  11. Phase 1/2a: ADA incidence

    the proportion of participants having treatment-emergent ADA.

    Time frame: within 8 cycles (each cycle is 21 days or 14 days)

07

Study locations

21 of 36 sites recruiting
  • Site USA12-0
    Los Angeles, California 90095, United States
    Recruiting
  • Site USA08-0
    Newport Beach, California 92663, United States
    Recruiting
  • Site USA06-0
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • Site USA02-0
    Florida City, Florida 32827, United States
    Recruiting
  • Site USA11-0
    Chicago, Illinois 60637, United States
    Recruiting
  • Site USA03
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Site USA05-0
    Philadelphia, Pennsylvania 19107, United States
    Not yet recruiting
  • Site USA07-0
    Nashville, Tennessee 37203, United States
    Recruiting
  • Site USA09-0
    West Valley City, Utah 84119, United States
    Recruiting
  • AUS03-0
    North Ryde, New South Wales 2109, Australia
    Recruiting
  • AUS01-0
    Randwick, New South Wales 2031, Australia
    Recruiting
  • AUS02-0
    Nedlands, Washington 6009, Australia
    Recruiting
  • Site CHN24-0
    Hefei, Anhui 230000, China
    Not yet recruiting
  • Site CHN39-0
    Hefei, Anhui 230031, China
    Not yet recruiting
  • Site CHN28-0
    Beijing, Beijing Municipality 100142, China
    Not yet recruiting
  • Site CHN13-0
    Jilin City, Changchun 130000, China
    Not yet recruiting
  • Site CHN16-0
    Chongqing, Chongqing Municipality 400030, China
    Recruiting
  • Site CHN20-0
    Fuzhou, Fujian 350000, China
    Recruiting
  • Site CHN32-0
    Nanning, Guangxi 530012, China
    Not yet recruiting
  • Site CHN08-0
    Harbin, Heilongjiang 150001, China
    Recruiting
  • Site CHN23-0
    Harbin, Heilongjiang 150001, China
    Not yet recruiting
  • Site CHN03-0
    Luoyang, Henan 471000, China
    Recruiting
  • Site CHN09-0
    Zhengzhou, Henan 450000, China
    Not yet recruiting
  • Site CHN25-0
    Zhengzhou, Henan 451191, China
    Not yet recruiting
  • Site CHN34-0
    Wuhan, Hubei 430079, China
    Recruiting
  • Site CHN21-0
    Changsha, Hunan 410011, China
    Recruiting
  • Site CHN31-0
    Shenyang, Liaoning 110000, China
    Not yet recruiting
  • Site CHN29-0
    Jinan, Shandong 250117, China
    Not yet recruiting
  • Site CHN26-0
    Linyi, Shandong 276034, China
    Recruiting
  • Site CHN01-0
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
  • Site CHN15-0
    Shanghai, Shanghai Municipality 200030, China
    Recruiting
  • Site CHN18-0
    Chengdu, Sichuan 610041, China
    Recruiting
  • Site CHN38-0
    Tianjin, Tianjin Municipality 300000, China
    Not yet recruiting
  • Site CHN19-0
    Kunming, Yunnan 650118, China
    Not yet recruiting
  • Site CHN17-0
    Hangzhou, Zhejiang 310005, China
    Not yet recruiting
  • Site CHN37-0
    Hangzhou, Zhejiang 310009, China
    Not yet recruiting
08

References and documents

Publications

  • Li C, Yao J, Yang J, Zhang Y, Qiu Y, Zhu Z, Hua H. Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 x PD-L1 Antibody-Drug Conjugate. Clin Cancer Res. 2025 Aug 14;31(16):3581-3593. doi: 10.1158/1078-0432.CCR-25-0634. PubMed 40499141 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Feb 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 6, 2024
First posted
Aug 15, 2024
StartActual
Sep 3, 2024
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06554795
Lead sponsor
DualityBio Inc.
Responsible party
Sponsor
First posted
Aug 15, 2024
Start date
Sep 3, 2024
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jun 5, 2026

Study contacts

Milly Zang
Contact
milly.zang@dualitybiologics.com
201-503-5410
Cathy Li
Contact
cathy.li@dualitybiologics.com
201-503-5410
Lily Hu
study director · DualityBio Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion